[의학신문·일간보사=김영주 기자]Daewoong Pharmaceutical (CEO Jeon Seung-ho and Lee Chang-jae) held an online New Year’s opening ceremony on the morning of the 3rd and presented four management policies under the slogan of ‘Leap as a global healthcare company through challenge and innovation’.
CEO Jeon Seung-ho (Photo), in his New Year’s address, said, “In 2021, despite the difficult environment due to Corona 19, through the performance of each business of ETC (ETC), over-the-counter (OTC), and Nabota, we achieved a 1 trillion club in sales and achieved the highest operating profit since its foundation. “This year is a time when it is necessary to unite the company’s innovation engines to achieve Daewoong Pharmaceutical’s ‘Global 2025 Vision’ and to achieve continuous sales growth amidst the ever-changing environment due to COVID-19.” did.
As Daewoong Pharmaceutical’s 2022 management policy, CEO Jeon presented ▲improving customer value, ▲cultivating talent to lead change, ▲innovating performance through open collaboration, and ▲creating value for global innovative new drugs.
CEO Jeon said, “We must always become a company that provides greater value by keeping eye level with customers.” “Let’s improve customer value in all areas from disease prevention, treatment, and follow-up management by developing new technologies and integrating various platforms.” he emphasized.
“The growth of employees is also important,” he said. “If there is a willingness to solve problems with passion and will, even if a wave of big change comes, we will be able to break through it with innovation and creativity as a weapon.”
In addition, “Strengthening our ability to position ourselves as a global leader through continuous open collaboration” and “Gastroesophageal reflux disease drug ‘Fexuclu Tab’ scheduled to be released in the first half of the year, diabetes drug ‘Inavogliflozin’ and pulmonary fibrosis new drug We will accelerate our leap forward as a global big pharmaceutical company through visualization of innovative new drug outcomes in various fields such as new drugs for autoimmune diseases and autoimmune diseases.”
.
